Clinical Development Marketing White Paper 
PPD
JULY 29, 2025
These elongated timelines are contributing to soaring costs, with the average cost of developing a new drug rising to approximately $2.6 For sponsors, the imperative to streamline development processes and improve clinical development speed and efficiency has never been more critical. billion (versus $1-1.5
Conversations in Drug Development Trends
MAY 15, 2025
Have you considered the multiple associated benefits and implications in the context of your novel drug development plan? This blog highlights some of the key themes discussed in our white paper on the application process, From Concept to Market: The Strategic Role of an IND in Drug DevelopmentMoving Beyond “May Proceed.”
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
PPD
OCTOBER 8, 2024
The highly dynamic biotech industry has a core need to remain as flexible and agile as possible across the spectrum of clinical development activities. One primary way these companies create a nimble and adaptive environment is by outsourcing some portion of clinical development functions.
Conversations in Drug Development Trends
DECEMBER 20, 2023
You can learn more about biomarkers and how to use them in oncology studies in this white paper. Optimize Your Oncology Program with Worldwide Matt Cooper and our global team of oncology experts have dedicated their careers to oncology clinical development programs.
PPD
OCTOBER 2, 2024
Efficient and effective clinical operations are the backbone of successful clinical trials, and today’s biopharmaceutical, biotech and medical device organizations have a range of options to meet their needs in this critical area.
Conversations in Drug Development Trends
MARCH 7, 2024
Understanding the nuances of each pathway is crucial for small to midsize companies aiming to navigate the complexities of global clinical development successfully. For additional insights, download our full white paper, “ First-in-Human Studies: IND or CTA? ”.
PPD
JUNE 17, 2024
For a developer using an FSO model but looking to evolve the way they undertake clinical trials, a bespoke FSP/FSO hybrid solution can provide a smooth transition to FSP outsourcing. This approach enables unbroken continuity of support and resources across clinical trial operations.
Expert insights. Personalized for you.
Let's personalize your content